Related Experiment Video
Updated: Feb 25, 2026
Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
Early aspirin use and the development of cardiac allograft vasculopathy
Miae Kim1, Brian A Bergmark2, Thomas A Zelniker2
1Center for Advanced Heart Disease, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Insights
Early aspirin use after heart transplant may reduce cardiac allograft vasculopathy (CAV) risk. This study found aspirin-treated patients had significantly lower rates of moderate to severe CAV, suggesting a protective effect.
Area of Science:
- Cardiology
- Transplantation Immunology
- Pharmacology
Background:
- Cardiac allograft vasculopathy (CAV) is a major complication following orthotopic heart transplantation (OHT).
- The impact of aspirin on CAV development and progression is not well understood.
Purpose of the Study:
- To investigate the association between early aspirin therapy and the incidence of moderate to severe CAV after OHT.
- To evaluate the effect of aspirin on long-term outcomes in heart transplant recipients.
Main Methods:
- A cohort of 120 OHT patients was followed for a median of 7 years.
- Patients were categorized based on early aspirin treatment (≥6 months in the first year post-transplant).
- Propensity score weighting (IPTW) was used to adjust for baseline differences and analyze the association with CAV development.
Main Results:
- Aspirin use was associated with a significantly lower rate of moderate to severe CAV at 5 years (95.9% event-free survival with aspirin vs. 79.6% without).
- IPTW-adjusted analysis revealed a strong inverse association between aspirin and moderate to severe CAV (aHR 0.13).
- A trend towards reduced CAV of any severity was also observed with aspirin use (aHR 0.50).
Conclusions:
- Early aspirin exposure following OHT may be linked to a decreased risk of developing moderate to severe CAV.
- These findings suggest a potential benefit of aspirin in managing CAV.
- Further prospective studies are needed to confirm these observations in controlled settings.
Background:
Cardiac allograft vasculopathy (CAV) remains a leading cause of morbidity and mortality after orthotopic heart transplantation (OHT). Little is known about the influence of aspirin on clinical expression of CAV.
Methods:
We followed 120 patients with OHT at a single center for a median of 7 years and categorized them by the presence or absence of early aspirin therapy post-transplant (aspirin treatment ≥6 months in the first year). The association between aspirin use and time to the primary end-point of angiographic moderate or severe CAV (International Society for Heart and Lung Transplantation grade ≥2) was investigated. Propensity scores for aspirin treatment were estimated using boosting models and applied by inverse probability of treatment weighting (IPTW).
Results:
Despite a preponderance of risk factors for CAV among patients receiving aspirin (male sex, ischemic heart disease as the etiology of heart failure, and smoking), aspirin therapy was associated with a lower rate of moderate or severe CAV at 5 years. Event-free survival was 95.9% for patients exposed to aspirin compared with 79.6% for patients without aspirin exposure (log-rank p = 0.005). IPTW-weighted Cox regression revealed a powerful inverse association between aspirin use and moderate to severe CAV (adjusted hazard ratio 0.13; 95% confidence interval 0.03-0.59), which was directionally consistent for CAV of any severity (adjusted hazard ratio 0.50; 95% confidence interval 0.23-1.08).
Conclusions:
This propensity score-based comparative observational analysis suggests that early aspirin exposure may be associated with a reduced risk of development of moderate to severe CAV. These findings warrant prospective validation in controlled investigations.
